Disclosed embodiments relate generally to the treatment of wounds using negative pressure wound therapy, in particular the prevention of fluid absorption in selected regions of a negative pressure wound therapy dressing.
The treatment of open or chronic wounds that are too large to spontaneously close or otherwise fail to heal by means of applying negative pressure to the site of the wound is well known in the art. Negative pressure wound therapy (NPWT) systems currently known in the art commonly involve placing a cover that is impermeable or semi-permeable to fluids over the wound, using various means to seal the cover to the tissue of the patient surrounding the wound, and connecting a source of negative pressure (such as a vacuum pump) to the cover in a manner so that negative pressure is created and maintained under the cover. It is believed that such negative pressures promote wound healing by facilitating the formation of granulation tissue at the wound site and assisting the body's normal inflammatory process while simultaneously removing excess fluid, which may contain adverse cytokines and/or bacteria. However, further improvements in NPWT are needed to fully realize the benefits of treatment.
Many different types of wound dressings are known for aiding in NPWT systems. These different types of wound dressings include many different types of materials and layers, for example, gauze, pads, foam pads or multi-layer wound dressings. One example of a multi-layer wound dressing is the PICO dressing, available from Smith & Nephew, which includes a superabsorbent layer beneath a backing layer to provide a canister-less system for treating a wound with NPWT. The wound dressing may be sealed to a suction port providing connection to a length of tubing, which may be used to pump fluid out of the dressing and/or to transmit negative pressure from a pump to the wound dressing.
However, in some wound dressings the absorbent layer fills up with fluid in an unpredictable, and often, non-uniform manner. It may be desirable, in some situations, to more easily prevent fluid from reaching certain areas of the wound dressing and/or certain portions of the absorbent layer. Current dressings have limited and/or unsatisfactory methods of controlling fluid paths in the absorbent layer.
Embodiments of this disclosure include wound dressing apparatuses and methods of manufacturing and utilizing the same. Particular embodiments are directed to wound dressing apparatuses and methods of using the same having an absorbent area for retaining wound exudate within the wound dressing, and a negative pressure source in fluid communication with the absorbent area. The negative pressure source may be connected to the wound dressing via a connector attached to the wound dressing, or the negative pressure source may be on or within the wound dressing itself.
According to some embodiments, there is provided a wound dressing including a wound contact layer configured to be positioned in contact with a wound; a first area over the wound contact layer that includes a lower spacer layer and an absorbent layer; a second area over the wound contact layer that includes an optional plurality of spacer layers and a negative pressure source and/or electronic components positioned within or between the plurality of spacer layers, wherein the first area is positioned adjacent to the second area and separated by a partition, wherein the partition is formed by an epoxy material applied to one or more layers of the first area and/or the second area; and a cover layer configured to cover and form a seal over the wound contact layer, the first area, and the second area.
Wound dressing of the preceding paragraph can include one or more of the following features. In some embodiments of a wound dressing, the epoxy material includes a flexible hydrophobic material. In some embodiments of a wound dressing, the epoxy material includes a silicone adhesive. In embodiments, the wound treatment may further include an upper spacer layer configured to cover the first area and the second area and to allow air to be communicated between the first area and second area around the partition. In some embodiments of a wound dressing, the plurality of spacer layers in the second area include a third spacer layer beneath the negative pressure source and/or electronic components and a fourth spacer layer positioned above the negative pressure source and/or electronic components, wherein the fourth spacer layer includes one or more cutouts or recesses configured to receive the negative pressure source and/or electronic components. In embodiments, the wound treatment apparatus may further include one or more user interface components configured to allow a user to operate the negative pressure source and/or electronic components.
According to another embodiment there is provided, a wound dressing including a wound contact layer configured to be positioned in contact with a wound; a first area over the wound contact layer that includes a lower spacer layer and an absorbent layer; a second area over the wound contact layer including an optional plurality of layers and a negative pressure source and/or electronic components positioned within or between the plurality of layers, wherein the first area is positioned adjacent to the second area; and wherein one or more layers of the plurality of layers of the second area include a hydrophobic material surrounding the negative pressure source and/or electronic components; and a cover layer configured to cover and form a seal over the wound contact layer, the first area, and the second area.
Wound dressings of any of the preceding paragraphs can include one or more of the following features. In some embodiments of a wound dressing, the absorbent layer includes a portion adjacent to the second area and wherein the portion adjacent to the second area includes a hydrophobic material. In certain embodiments, the wound treatment apparatus may further include an upper spacer layer configured to cover the first area and the second area and to allow air to be communicated between the first area and second area. In some embodiments, the wound dressing the plurality of layers in the second area include a third spacer layer beneath the negative pressure source and/or electronic components and a fourth spacer layer positioned above the negative pressure source and/or electronic components, wherein the fourth spacer layer includes one or more cutouts or recesses configured to receive the negative pressure source and/or electronic components. In some embodiments, the wound dressing wherein the plurality of layers in the second area include a third spacer layer beneath the negative pressure source and/or electronic components, wherein the third spacer layer and the lower spacer layer are one continuous layer positioned below the absorbent layer and the negative pressure source and/or electronic components and above the wound contract layer. In embodiments, the wound treatment apparatus may further include one or more user interface components configured to allow a user to operate the negative pressure source and/or electronic components.
Embodiments disclosed herein relate to apparatuses and methods of treating a wound with reduced pressure, including a source of negative pressure and wound dressing components and apparatuses. The apparatuses and components comprising the wound overlay and packing materials, if any, are sometimes collectively referred to herein as dressings.
Some embodiments disclosed herein relate to wound therapy for a human or animal body. Therefore, any reference to a wound herein can refer to a wound on a human or animal body, and any reference to a body herein can refer to a human or animal body. The term “wound” as used herein, in addition to having its broad ordinary meaning, includes any body part of a patient that may be treated using negative pressure. Wounds include, but are not limited to, open wounds, incisions, lacerations, abrasions, contusions, burns, diabetic ulcers, pressure ulcers, stoma, surgical wounds, trauma and venous ulcers or the like. Treatment of such wounds can be performed using negative pressure wound therapy, wherein a reduced or negative pressure can be applied to the wound to facilitate and promote healing of the wound. It will also be appreciated that the fluidic connector and methods as disclosed herein may be applied to other parts of the body, and are not necessarily limited to treatment of wounds.
Treatment of such wounds can be performed using negative pressure wound therapy, wherein a reduced or negative pressure can be applied to the wound to facilitate and promote healing of the wound. It will also be appreciated that the wound dressing and methods as disclosed herein may be applied to other parts of the body, and are not necessarily limited to treatment of wounds. Certain embodiments of this application relate to a wound treatment apparatus employing a wound dressing and a fluidic connector, and to methods of using the same.
It will be understood that embodiments of the present disclosure are generally applicable to use in topical negative pressure (“TNP”) therapy systems. Briefly, negative pressure wound therapy assists in the closure and healing of many forms of “hard to heal” wounds by reducing tissue oedema; encouraging blood flow and granular tissue formation; removing excess exudate and may reduce bacterial load (and thus infection risk). In addition, the therapy allows for less disturbance of a wound leading to more rapid healing. TNP therapy systems may also assist on the healing of surgically closed wounds by removing fluid and by helping to stabilize the tissue in the apposed position of closure. A further beneficial use of TNP therapy can be found in grafts and flaps where removal of excess fluid is important and close proximity of the graft to tissue is required in order to ensure tissue viability.
As is used herein, reduced or negative pressure levels, such as-X mmHg, represent pressure levels relative to normal ambient atmospheric pressure, which can correspond to 760 mmHg (or 1 atm, 29.93 mmHg, 101.325 kPa, 14.696 psi, etc.). Accordingly, a negative pressure value of −X mmHg reflects absolute pressure that is X mmHg below 760 mmHg or, in other words, an absolute pressure of (760−X) mmHg. In addition, negative pressure that is “less” or “smaller” than X mmHg corresponds to pressure that is closer to atmospheric pressure (e.g., −40 mmHg is less than −60 mmHg). Negative pressure that is “more” or “greater” than −X mmHg corresponds to pressure that is further from atmospheric pressure (e.g., −80 mmHg is more than −60 mmHg). In some embodiments, local ambient atmospheric pressure is used as a reference point, and such local atmospheric pressure may not necessarily be, for example, 760 mmHg.
The negative pressure range for some embodiments of the present disclosure can be approximately −80 mmHg, or between about −20 mmHg and −200 mmHg Note that these pressures are relative to normal ambient atmospheric pressure, which can be 760 mmHg Thus, −200 mmHg would be about 560 mmHg in practical terms. In some embodiments, the pressure range can be between about −40 mmHg and −150 mmHg. Alternatively a pressure range of up to −75 mmHg, up to −80 mmHg or over −80 mmHg can be used. Also in other embodiments a pressure range of below −75 mmHg can be used. Alternatively, a pressure range of over approximately −100 mmHg, or even−150 mmHg, can be supplied by the negative pressure apparatus.
With reference initially to
As shown in the embodiment of
As illustrated in
Some embodiments of the wound contact layer 222 may also act as a carrier for an optional lower and upper adhesive layer (not shown). For example, a lower pressure sensitive adhesive may be provided on the lower surface 224 of the wound dressing 100 whilst an upper pressure sensitive adhesive layer may be provided on the upper surface 223 of the wound contact layer. The pressure sensitive adhesive, which may be a silicone, hot melt, hydrocolloid or acrylic based adhesive or other such adhesives, may be formed on both sides or optionally on a selected one or none of the sides of the wound contact layer. When a lower pressure sensitive adhesive layer is utilized may be helpful to adhere the wound dressing 100 to the skin around a wound site. In some embodiments, the wound contact layer may include perforated polyurethane film. The lower surface of the film may be provided with a silicone pressure sensitive adhesive and the upper surface may be provided with an acrylic pressure sensitive adhesive, which may help the dressing maintain its integrity. In some embodiments, a polyurethane film layer may be provided with an adhesive layer on both its upper surface and lower surface, and all three layers may be perforated together.
A layer 226 of porous material can be located above the wound contact layer 222. This porous layer, or transmission layer, 226 allows transmission of fluid including liquid and gas away from a wound site into upper layers of the wound dressing. In certain embodiments, the transmission layer 226 preferably ensures that an open air channel can be maintained to communicate negative pressure over the wound area even when the absorbent layer has absorbed substantial amounts of exudates. The layer 226 should preferably remain open under the typical pressures that will be applied during negative pressure wound therapy as described above, so that the whole wound site sees an equalized negative pressure. The layer 226 may be formed of a material having a three dimensional structure. For example, a knitted or woven spacer fabric (for example Baltex 7970 weft knitted polyester) or a non-woven fabric could be used.
In some embodiments, the transmission layer 226 includes a 3D polyester spacer fabric layer including a top layer (that is to say, a layer distal from the wound-bed in use) which is a 84/144 textured polyester, and a bottom layer (that is to say, a layer which lies proximate to the wound bed in use) which is a 10 denier flat polyester and a third layer formed sandwiched between these two layers which is a region defined by a knitted polyester viscose, cellulose or the like monofilament fiber. Other materials and other linear mass densities of fiber could of course be used.
Whilst reference is made throughout this disclosure to a monofilament fiber it will be appreciated that a multistrand alternative could of course be utilized. The top spacer fabric thus has more filaments in a yarn used to form it than the number of filaments making up the yarn used to form the bottom spacer fabric layer.
This differential between filament counts in the spaced apart layers helps control moisture flow across the transmission layer. Particularly, by having a filament count greater in the top layer, that is to say, the top layer is made from a yarn having more filaments than the yarn used in the bottom layer, liquid tends to be wicked along the top layer more than the bottom layer. In use, this differential tends to draw liquid away from the wound bed and into a central region of the dressing where the absorbent layer 221 helps lock the liquid away or itself wicks the liquid onwards towards the cover layer where it can be transpired.
In some embodiments, preferably, to improve the liquid flow across the transmission layer 226 (that is to say perpendicular to the channel region formed between the top and bottom spacer layers) the 3D fabric may be treated with a dry cleaning agent (such as, but not limited to, Perchloro Ethylene) to help remove any manufacturing products such as mineral oils, fats and/or waxes used previously which might interfere with the hydrophilic capabilities of the transmission layer. In some embodiments, an additional manufacturing step can subsequently be carried in which the 3D spacer fabric is washed in a hydrophilic agent (such as, but not limited to, Feran Ice 30 g/l available from the Rudolph Group). This process step helps ensure that the surface tension on the materials is so low that liquid such as water can enter the fabric as soon as it contacts the 3D knit fabric. This also aids in controlling the flow of the liquid insult component of any exudates.
A layer 221 of absorbent material is provided above the transmission layer 226. The absorbent material, which include a foam or non-woven natural or synthetic material, and which may optionally include a super-absorbent material, forms a reservoir for fluid, particularly liquid, removed from the wound site. In some embodiments, the layer 10 may also aid in drawing fluids towards the backing layer 220.
The material of the absorbent layer 221 may also prevent liquid collected in the wound dressing 100 from flowing freely within the dressing. In some embodiments, the material of the absorbent layer 221 preferably acts so as to contain any liquid collected within the dressing. The absorbent layer 221 also helps distribute fluid throughout the layer via a wicking action so that fluid is drawn from the wound site and stored throughout the absorbent layer. This helps prevent agglomeration in areas of the absorbent layer. The capacity of the absorbent material must be sufficient to manage the exudate flow rate of a wound when negative pressure is applied. Since in use the absorbent layer experiences negative pressures the material of the absorbent layer is chosen to absorb liquid under such circumstances. A number of materials exist that are able to absorb liquid when under negative pressure, for example super absorber material. The absorbent layer 221 may typically be manufactured from ALLEVYN™ foam, Freudenberg 114-224-4 and/or Chem-Posite™ 11C-450. In some embodiments, the absorbent layer 221 may include a composite comprising super absorbent powder, fibrous material such as cellulose, and bonding fibers. In certain embodiments, a preferred composite is an airlaid, thermally-bonded composite.
In some embodiments, the absorbent layer 221 is a layer of non-woven cellulose fibers having super-absorbent material in the form of dry particles dispersed throughout. Use of the cellulose fibers introduces fast wicking elements which help quickly and evenly distribute liquid taken up by the dressing. The juxtaposition of multiple strand-like fibers leads to strong capillary action in the fibrous pad which helps distribute liquid. In this way, the super-absorbent material is efficiently supplied with liquid. The wicking action also assists in bringing liquid into contact with the upper cover layer to aid increase transpiration rates of the dressing.
In some embodiments, an aperture, hole, or orifice 227 is preferably provided in the backing layer 220 to allow a negative pressure to be applied to the dressing 100. In certain embodiments, the fluidic connector 110 is preferably attached or sealed to the top of the backing layer 220 over the orifice 227 made into the dressing 100, and communicates negative pressure through the orifice 227. A length of tubing may be coupled at a first end to the fluidic connector 110 and at a second end to a pump unit (not shown) to allow fluids to be pumped out of the dressing. Where the fluidic connector is adhered to the top layer of the wound dressing, a length of tubing may be coupled at a first end of the fluidic connector such that the tubing, or conduit, extends away from the fluidic connector parallel or substantially to the top surface of the dressing. The fluidic connector 110 may be adhered and sealed to the backing layer 220 using an adhesive such as an acrylic, cyanoacrylate, epoxy, UV curable or hot melt adhesive. The fluidic connector 110 may be formed from a soft polymer, for example a polyethylene, a polyvinyl chloride, a silicone or polyurethane having a hardness of 30 to 90 on the Shore A scale. In some embodiments, the fluidic connector 110 may be made from a soft or conformable material.
In some embodiments, the absorbent layer 221 includes at least one through hole 228 located so as to underlie the fluidic connector 110. The through hole 228 may in some embodiments be the same size as the opening 227 in the backing layer, or may be bigger or smaller. As illustrated in
The aperture or through-hole 228 can be provided in the absorbent layer 221 beneath the orifice 227 such that the orifice is connected directly to the transmission layer 226. This allows the negative pressure applied to the fluidic connector 110 to be communicated to the transmission layer 226 without passing through the absorbent layer 221. This ensures that the negative pressure applied to the wound site is not inhibited by the absorbent layer as it absorbs wound exudates. In other embodiments, no aperture may be provided in the absorbent layer 221, or alternatively a plurality of apertures underlying the orifice 227 may be provided. In further alternative embodiments, additional layers such as another transmission layer or an obscuring layer such as described in International Patent Publication WO2014020440 may be provided over the absorbent layer 221 and beneath the backing layer 220.
In some embodiments, the backing layer 220 is preferably gas impermeable, but moisture vapor permeable, and can extend across the width of the wound dressing 100. The backing layer 220, which may for example be a polyurethane film (for example, Elastollan SP9109) having a pressure sensitive adhesive on one side, is impermeable to gas and this layer thus operates to cover the wound and to seal a wound cavity over which the wound dressing is placed. In this way an effective chamber is made between the backing layer 220 and a wound site where a negative pressure can be established. In certain embodiments, the backing layer 220 is preferably sealed to the wound contact layer 222 in a border region around the circumference of the dressing, ensuring that no air is drawn in through the border area, for example via adhesive or welding techniques. The backing layer 220 protects the wound from external bacterial contamination (bacterial barrier) and allows liquid from wound exudates to be transferred through the layer and evaporated from the film outer surface. In some implementations, the backing layer 220 preferably includes two layers; a polyurethane film and an adhesive pattern spread onto the film. In certain embodiments, the polyurethane film is preferably moisture vapor permeable and may be manufactured from a material that has an increased water transmission rate when wet. In some embodiments the moisture vapor permeability of the backing layer increases when the backing layer becomes wet. The moisture vapor permeability of the wet backing layer may be up to about ten times more than the moisture vapor permeability of the dry backing layer.
The absorbent layer 221 may be of a greater area than the transmission layer 226, such that the absorbent layer overlaps the edges of the transmission layer 226, thereby ensuring that the transmission layer does not contact the backing layer 220. This provides an outer channel of the absorbent layer 221 that is in direct contact with the wound contact layer 222, which aids more rapid absorption of exudates to the absorbent layer. Furthermore, this outer channel ensures that no liquid is able to pool around the circumference of the wound cavity, which may otherwise seep through the seal around the perimeter of the dressing leading to the formation of leaks. In some embodiments, the transmission layer 226 can be a greater area than the absorbent layer 221, such that the transmission layer 226 extends beyond the edges of the absorbent layer 221. The dressing can include one or more transmission layers positioned above or below the absorbent layer. As illustrated in
As shown in
In particular for some embodiments with a single fluidic connector 110 and through hole, it may be preferable for the fluidic connector 110 and through hole to be located in an off-center position as illustrated in
Turning now to the fluidic connector 110, some embodiments preferably include a sealing surface 216, a bridge 211 (corresponding to bridge 120 in
Some embodiments may further include an optional second fluid passage positioned above the first fluid passage 212. For example, some embodiments may provide for an air leak may be disposed at the proximal end of the top layer that is configured to provide an air path into the first fluid passage 212 and dressing 100, similar to the suction adapter described in U.S. Pat. No. 8,801,685, which is incorporated by reference herein in its entirety.
In some embodiments, preferably, the fluid passage 212 is constructed from a compliant material that is flexible and that also permits fluid to pass through it if the spacer is kinked or folded over. Suitable materials for the fluid passage 212 include without limitation foams, including open-cell foams such as polyethylene or polyurethane foam, meshes, 3D knitted fabrics, non-woven materials, and fluid channels. In some embodiments, the fluid passage 212 may be constructed from materials similar to those described above in relation to the transmission layer 226. Advantageously, such materials used in the fluid passage 212 not only permit greater patient comfort, but may also provide greater kink resistance, such that the fluid passage 212 is still able to transfer fluid from the wound toward the source of negative pressure while being kinked or bent.
In some embodiments, the fluid passage 212 may be comprised of a wicking fabric, for example a knitted or woven spacer fabric (such as a knitted polyester 3D fabric, Baltex 7970®, or Gehring 879®) or a nonwoven fabric. These materials selected are preferably suited to channeling wound exudate away from the wound and for transmitting negative pressure and/or vented air to the wound site, and may also confer a degree of kinking or occlusion resistance to the fluid passage 212. In some embodiments, the wicking fabric may have a three-dimensional structure, which in some cases may aid in wicking fluid or transmitting negative pressure. In certain embodiments, including wicking fabrics, these materials remain open and capable of communicating negative pressure to a wound area under the typical pressures used in negative pressure therapy, for example between 40 to 150 mmHg. In some embodiments, the wicking fabric may include several layers of material stacked or layered over each other, which may in some cases be useful in preventing the fluid passage 212 from collapsing under the application of negative pressure. In certain embodiments, the wicking fabric used in the fluid passage 212 may be between 1.5 mm and 6 mm; more preferably, the wicking fabric may be between 3 mm and 6 mm thick, and may be comprised of either one or several individual layers of wicking fabric. In other embodiments, the fluid passage 212 may be between 1.2-3 mm thick, and preferably thicker than 1.5 mm Some embodiments, for example a suction adapter used with a dressing which retains liquid such as wound exudate, may employ hydrophobic layers in the fluid passage 212, and only gases may travel through the fluid passage 212. Additionally, and as described previously, the materials used in some embodiments of the system are preferably conformable and soft, which may help to avoid pressure ulcers and other complications which may result from a wound treatment system being pressed against the skin of a patient.
In some embodiments, preferably, the filter element 214 is impermeable to liquids, but permeable to gases, and is provided to act as a liquid barrier and to ensure that no liquids are able to escape from the wound dressing 100. The filter element 214 may also function as a bacterial bather. Typically the pore size is 0.2 μm. Suitable materials for the filter material of the filter element 214 include 0.2 micron Gore™ expanded PTFE from the MMT range, PALL Versapore™ 200R, and Donaldson™ TX6628. Larger pore sizes can also be used but these may require a secondary filter layer to ensure full bioburden containment. As wound fluid contains lipids it is preferable in some embodiments, though not essential, to use an oleophobic filter membrane for example 1.0 micron MMT-332 prior to 0.2 micron MMT-323. This prevents the lipids from blocking the hydrophobic filter. The filter element can be attached or sealed to the port and/or the cover film over the orifice. For example, the filter element 214 may be molded into the fluidic connector 110, or may be adhered to one or both of the top of the cover layer and bottom of the suction adapter 110 using an adhesive such as, but not limited to, a UV cured adhesive.
It will be understood that other types of material could be used for the filter element 214. More generally a microporous membrane can be used which is a thin, flat sheet of polymeric material, this contains billions of microscopic pores. Depending upon the membrane chosen these pores can range in size from 0.01 to more than 10 micrometers. Microporous membranes are available in both hydrophilic (water filtering) and hydrophobic (water repellent) forms. In some embodiments, filter element 214 includes a support layer and an acrylic co-polymer membrane formed on the support layer. Preferably the wound dressing 100 according to certain embodiments uses microporous hydrophobic membranes (MHMs). Numerous polymers may be employed to form MHMs. For example, the MHMs may be formed from one or more of PTFE, polypropylene, PVDF and acrylic copolymer. All of these optional polymers can be treated in order to obtain specific surface characteristics that can be both hydrophobic and oleophobic. As such these will repel liquids with low surface tensions such as multi-vitamin infusions, lipids, surfactants, oils and organic solvents.
MHMs block liquids whilst allowing air to flow through the membranes. They are also highly efficient air filters eliminating potentially infectious aerosols and particles. A single piece of MHM is well known as an option to replace mechanical valves or vents. Incorporation of MHMs can thus reduce product assembly costs improving profits and costs/benefit ratio to a patient.
The filter element 214 may also include an odor absorbent material, for example activated charcoal, carbon fiber cloth or Vitec Carbotec-RT Q2003073 foam, or the like. For example, an odor absorbent material may form a layer of the filter element 214 or may be sandwiched between microporous hydrophobic membranes within the filter element. The filter element 214 thus enables gas to be exhausted through the orifice. Liquid, particulates and pathogens however are contained in the dressing.
In some embodiments, a pump and/or other electronic components can be configured to be positioned adjacent to or next to the absorbent and/or transmission layers so that the pump and/or other electronic components are still part of a single apparatus to be applied to a patient, but the pump and/or other electronics are positioned away from the wound site. In some embodiments, a pump and/or other electronic components can be positioned above or mounted above the absorbent and/or transmission layers described above.
The absorbent area 1360 of the dressing can include a second spacer layer 1311 or lower spacer layer and an absorbent layer 1322 positioned above the wound contact layer 1310. The second spacer layer 1311 can allow for an open air path over the wound site. The absorbent layer 1322 can include a super absorber positioned in the absorbent area 1360 of the dressing. The absorbent layer 1322 can retain wound fluid within thereby preventing fluid passage of wound exudates into the electronics area 1361 of the dressing. The wound fluids can flow through the wound contact layer 1310, to the lower spacer layer 1311, and into the absorbent layer 1322. The wound fluids are then spread throughout the absorbent layer 1322 and retained in the absorbent layer 1322 as shown by the directional arrows for wound fluids in
The electronics area 1361 of the dressing can include a plurality of layers of spacer material 1351 and electronic components 1350 embedded within the plurality of layers of spacer material 1351. The layers of spacer material can have recesses or cut outs to embed the electronic components within whilst providing structure to prevent collapse. The electronic components 1350 can include a pump, power source, controller, and/or an electronics package.
In some embodiments, a partition, divider, and/or other separating material or device can be positioned between the absorbent area and the electronics area. In some embodiments, the separating material can be a partition 1362 as shown in
A pump exhaust 1370 can be provided to exhaust air from the pump to the outside of the dressing. The pump exhaust can be in communication with the electronics area 1361 and the outside of the dressing. In some embodiments, the pump exhaust 1370 can be a flexible fluidic connector that includes a 3D material that allows for pressure to be applied without collapse of the exhaust port. Examples of an application where additional disclosure relating to the 3D material can be found include US Publication No. 2015/0141941, titled “Apparatuses and Methods for Negative Pressure Wound Therapy” published on May 21, 2015. The disclosure of this patent is hereby incorporated by reference in its entirety.
In certain embodiments, such as described above in
In certain embodiments, fluid saturation of the absorbent layer may be impeded by applying a glue such as a cyanoacrylate Super Glue (for example Loctite, by Henkel) onto the backing layer. Herein this section and throughout the specification, the term “glue” will be used to indicate an adhesive such as Super Glue or any cyanoacrylate glue. Application of the glue affects the underlying absorbent layer by preventing fluid from being absorbed in the area below the glue. In some embodiments, the glue prevents certain areas of the absorbent material from swelling with fluid. Glue may be applied to the backing layer or elsewhere in the dressing via any suitable method, such as via an applicator tube.
Turning to
In certain embodiments, the glue may be located at a variety of locations on the backing layer. For example, the glue may be applied all the way to the edge of the opening in the backing layer and/or cover the entire distal end of the fluidic connector to the outer edge of the fluidic connector. As described above, the glue may be applied around the rim of the opening in the form of a ring. In embodiments, the glue may be applied as a single line or as a series of lines. The glue may be applied as a spiral or as concentric circles on the backing layer. In certain embodiments, the glue may be applied as distinct, single lines or multiple lines. The glue may be applied to the underside of the backing layer in any manner described in relation to the topside of the backing layer.
In embodiments, the glue may be applied around the periphery of the backing layer, for example, the entire periphery, 50% of the entirety, or 25% of the entirety. In certain embodiments the glue may be applied to only a portion of the perimeter of the distal end fluidic connector, for example 25%, 50%, or 75%. The glue may be applied to create channels in the underlying absorbent layers to channel wound exudate to the opening in the backing layer. In certain embodiments, the glue may be applied under the applicator portion of the fluidic connector, but not the fluid passage. In embodiments, the glue may be applied to only the outermost ring of the applicator portion of the fluidic connector. In certain embodiments, the glue may be applied to the sealing surface of the fluidic connector. In further embodiments, the glue may be applied on the backing layer around but not under the fluidic connector.
In certain embodiments, the glue may be applied directly to the absorbent layer in any manner described herein this section or elsewhere in the specification, particularly as described above in relation to the backing layer. In some embodiments, the glue may be applied directly to the transmission layer in any manner described herein this section or elsewhere in the specification, particularly as described above in relation to the backing layer. In embodiments, the glue may be applied directly to the wound contact layer in any manner described herein this section or elsewhere in the specification, particularly as described above in relation to the backing layer.
Dressing materials to control fluid flow
As discussed with reference to
In some embodiments, the absorbent area and electronics area can be separated by using an epoxy material or similar material. The epoxy material can be used in a manner similar to the use of the glue as described above with reference to
In some embodiments, the wound dressing with incorporated pump and electronics does not include a dam or structure separating the electronics and absorbent area. The wound dressing can instead utilize hydrophobic or hydrophilic properties of the materials to control fluid flow and protect the electronics from the fluid within the dressing. In some embodiments, the wound dressing can include a lower spacer layer 1311 that extends from the absorbent area to the electronics area or a separate spacer layer between the electronics area and wound contact layer. Therefore, a lower spacer layer could be positioned between the absorbent layer and wound contact layer in the absorbent area and between the electronics and the wound contact layer in the electronics area. The lower spacer layer can be formed of, treated with, or coated with a hydrophilic agent as described above that directs the fluid through the spacer layer, into the absorbent layer, and away from the electronics.
In some embodiments, a portion of the absorbent layer can be formed of, treated with, or coated with a hydrophobic material. For example, the absorbent layer located in or directly adjacent to the electronics area can be formed of, treated with, or coated with a hydrophobic material to direct fluid away from the pump and/or electronics and prevent fluid from pooling around the pump and/or electronics. The portion of the absorbent layer that does not include a hydrophobic material may act as described with reference to
Features, materials, characteristics, or groups described in conjunction with a particular aspect, embodiment, or example are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The protection is not restricted to the details of any foregoing embodiments. The protection extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.
While certain embodiments have been described, these embodiments have been presented by way of example only, and are not intended to limit the scope of protection. Indeed, the novel methods and systems described herein may be embodied in a variety of other forms. Furthermore, various omissions, substitutions and changes in the form of the methods and systems described herein may be made. Those skilled in the art will appreciate that in some embodiments, the actual steps taken in the processes illustrated and/or disclosed may differ from those shown in the figures. Depending on the embodiment, certain of the steps described above may be removed, others may be added. Furthermore, the features and attributes of the specific embodiments disclosed above may be combined in different ways to form additional embodiments, all of which fall within the scope of the present disclosure.
Although the present disclosure includes certain embodiments, examples and applications, it will be understood by those skilled in the art that the present disclosure extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses and obvious modifications and equivalents thereof, including embodiments which do not provide all of the features and advantages set forth herein. Accordingly, the scope of the present disclosure is not intended to be limited by the specific disclosures of certain embodiments herein, and may be defined by claims as presented herein or as presented in the future.
This application is a continuation of U.S. application Ser. No. 16/328,180, filed Feb. 25, 2019, which is a U.S. national stage application of International Patent Application No. PCT/EP2017/071322, filed Aug. 24, 2017, which claims priority to U.S. Provisional Application No. 62/379,667, filed Aug. 25, 2016, which is hereby incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3874387 | Barbieri | Apr 1975 | A |
4224941 | Stivala | Sep 1980 | A |
4398910 | Blake et al. | Aug 1983 | A |
4534356 | Papadakis | Aug 1985 | A |
4569674 | Phillips et al. | Feb 1986 | A |
4624656 | Clark et al. | Nov 1986 | A |
4681562 | Beck et al. | Jul 1987 | A |
4767943 | Adler et al. | Aug 1988 | A |
4979944 | Luzsicza | Dec 1990 | A |
5055195 | Trasch et al. | Oct 1991 | A |
5055198 | Shettigar | Oct 1991 | A |
5056510 | Gilman | Oct 1991 | A |
5152757 | Eriksson | Oct 1992 | A |
5181905 | Flam | Jan 1993 | A |
5266928 | Johnson | Nov 1993 | A |
D357743 | Bilitz et al. | Apr 1995 | S |
5527293 | Zamierowski | Jun 1996 | A |
5549584 | Gross | Aug 1996 | A |
5636643 | Argenta et al. | Jun 1997 | A |
5643189 | Masini | Jul 1997 | A |
5779657 | Daneshvar | Jul 1998 | A |
5833646 | Masini | Nov 1998 | A |
5902256 | Benaron | May 1999 | A |
5964723 | Augustine | Oct 1999 | A |
6071267 | Zamierowski | Jun 2000 | A |
6142982 | Hunt et al. | Nov 2000 | A |
6168800 | Dobos et al. | Jan 2001 | B1 |
6183438 | Berguer | Feb 2001 | B1 |
6225523 | Masini | May 2001 | B1 |
6261276 | Reitsma | Jul 2001 | B1 |
6261283 | Morgan et al. | Jul 2001 | B1 |
6398767 | Fleischmann | Jun 2002 | B1 |
6458109 | Henley et al. | Oct 2002 | B1 |
6471982 | Lydon et al. | Oct 2002 | B1 |
6599262 | Masini | Jul 2003 | B1 |
6607495 | Skalak et al. | Aug 2003 | B1 |
6685681 | Lockwood et al. | Feb 2004 | B2 |
6787682 | Gilman | Sep 2004 | B2 |
6794554 | Sessions et al. | Sep 2004 | B2 |
6800074 | Henley et al. | Oct 2004 | B2 |
6855135 | Lockwood et al. | Feb 2005 | B2 |
6942633 | Odland | Sep 2005 | B2 |
6951553 | Bubb et al. | Oct 2005 | B2 |
6979324 | Bybordi et al. | Dec 2005 | B2 |
7004915 | Boynton et al. | Feb 2006 | B2 |
7022113 | Lockwood et al. | Apr 2006 | B2 |
7067709 | Murata et al. | Jun 2006 | B2 |
7070584 | Johnson et al. | Jul 2006 | B2 |
7087806 | Scheinberg et al. | Aug 2006 | B2 |
7108683 | Zamierowski | Sep 2006 | B2 |
7216651 | Argenta et al. | May 2007 | B2 |
7338482 | Lockwood et al. | Mar 2008 | B2 |
7361184 | Joshi | Apr 2008 | B2 |
7524315 | Blott et al. | Apr 2009 | B2 |
7553306 | Hunt et al. | Jun 2009 | B1 |
7569742 | Haggstrom et al. | Aug 2009 | B2 |
7611500 | Lina et al. | Nov 2009 | B1 |
7615036 | Joshi et al. | Nov 2009 | B2 |
D605775 | Koch et al. | Dec 2009 | S |
D608007 | Arbesman et al. | Jan 2010 | S |
7645253 | Gura et al. | Jan 2010 | B2 |
7687678 | Jacobs | Mar 2010 | B2 |
7699823 | Haggstrom et al. | Apr 2010 | B2 |
7776028 | Miller et al. | Aug 2010 | B2 |
7779625 | Joshi et al. | Aug 2010 | B2 |
D625422 | Arbesman et al. | Oct 2010 | S |
7837673 | Vogel | Nov 2010 | B2 |
7838717 | Haggstrom et al. | Nov 2010 | B2 |
7896864 | Lockwood et al. | Mar 2011 | B2 |
7922676 | Daskal et al. | Apr 2011 | B2 |
7922703 | Riesinger | Apr 2011 | B2 |
7942866 | Radl et al. | May 2011 | B2 |
7959624 | Riesinger | Jun 2011 | B2 |
7976519 | Bubb et al. | Jul 2011 | B2 |
8007257 | Heaton et al. | Aug 2011 | B2 |
8007481 | Schuessler et al. | Aug 2011 | B2 |
8062272 | Weston | Nov 2011 | B2 |
8062273 | Weston | Nov 2011 | B2 |
8080702 | Blott et al. | Dec 2011 | B2 |
8092441 | Sugito | Jan 2012 | B2 |
8118794 | Weston | Feb 2012 | B2 |
8158844 | McNeil | Apr 2012 | B2 |
8167869 | Wudyka | May 2012 | B2 |
8207392 | Haggstrom et al. | Jun 2012 | B2 |
8212100 | Moore | Jul 2012 | B2 |
8215929 | Shen et al. | Jul 2012 | B2 |
8323264 | Weston et al. | Dec 2012 | B2 |
8371829 | Jaeb et al. | Feb 2013 | B2 |
8372049 | Jaeb et al. | Feb 2013 | B2 |
8372050 | Jaeb et al. | Feb 2013 | B2 |
8404921 | Lee et al. | Mar 2013 | B2 |
8409160 | Locke et al. | Apr 2013 | B2 |
8414519 | Hudspeth et al. | Apr 2013 | B2 |
8419696 | Wilkes | Apr 2013 | B2 |
8425478 | Olson | Apr 2013 | B2 |
8439894 | Miller | May 2013 | B1 |
8444612 | Patel et al. | May 2013 | B2 |
8449508 | Coulthard et al. | May 2013 | B2 |
8460255 | Joshi et al. | Jun 2013 | B2 |
8500776 | Ebner | Aug 2013 | B2 |
8529548 | Blott et al. | Sep 2013 | B2 |
8545464 | Weston | Oct 2013 | B2 |
8545466 | Andresen et al. | Oct 2013 | B2 |
8569566 | Blott et al. | Oct 2013 | B2 |
8579872 | Coulthard et al. | Nov 2013 | B2 |
8603074 | Kagan | Dec 2013 | B2 |
8604265 | Locke et al. | Dec 2013 | B2 |
8628505 | Weston | Jan 2014 | B2 |
8641691 | Fink et al. | Feb 2014 | B2 |
8641693 | Locke et al. | Feb 2014 | B2 |
8702665 | Locke et al. | Apr 2014 | B2 |
8764732 | Hartwell | Jul 2014 | B2 |
8795257 | Coulthard et al. | Aug 2014 | B2 |
8808274 | Hartwell | Aug 2014 | B2 |
8814842 | Coulthard et al. | Aug 2014 | B2 |
8821458 | Locke et al. | Sep 2014 | B2 |
8829263 | Haggstrom et al. | Sep 2014 | B2 |
8870837 | Locke et al. | Oct 2014 | B2 |
8915895 | Jaeb et al. | Dec 2014 | B2 |
8961496 | Locke et al. | Feb 2015 | B2 |
8974429 | Gordon et al. | Mar 2015 | B2 |
9050209 | Coulthard et al. | Jun 2015 | B2 |
9061095 | Adie et al. | Jun 2015 | B2 |
9084845 | Adie et al. | Jul 2015 | B2 |
9089630 | Perkins et al. | Jul 2015 | B2 |
9168330 | Joshi et al. | Oct 2015 | B2 |
9198802 | Robinson et al. | Dec 2015 | B2 |
9220822 | Hartwell | Dec 2015 | B2 |
9259558 | Tsai | Feb 2016 | B2 |
9265665 | Robinson et al. | Feb 2016 | B2 |
9265867 | Coulthard et al. | Feb 2016 | B2 |
9283118 | Locke et al. | Mar 2016 | B2 |
9393354 | Freedman et al. | Jul 2016 | B2 |
9414968 | Heagle | Aug 2016 | B2 |
9421133 | Hu et al. | Aug 2016 | B2 |
9427505 | Askem et al. | Aug 2016 | B2 |
9452088 | Shulman et al. | Sep 2016 | B2 |
9452245 | Jaeb et al. | Sep 2016 | B2 |
9560975 | Mei et al. | Feb 2017 | B2 |
9629986 | Patel et al. | Apr 2017 | B2 |
D787690 | MacKay et al. | May 2017 | S |
9669138 | Joshi et al. | Jun 2017 | B2 |
9737649 | Begin et al. | Aug 2017 | B2 |
9770368 | Robinson et al. | Sep 2017 | B2 |
9795725 | Joshi et al. | Oct 2017 | B2 |
9814811 | Aalders et al. | Nov 2017 | B2 |
9844475 | Hartwell | Dec 2017 | B2 |
9925092 | Luckemeyer et al. | Mar 2018 | B2 |
RE46778 | Peron | Apr 2018 | E |
9956120 | Locke | May 2018 | B2 |
10004914 | Nettesheim et al. | Jun 2018 | B2 |
10016544 | Coulthard et al. | Jul 2018 | B2 |
10086117 | Locke et al. | Oct 2018 | B2 |
10123909 | Hartwell | Nov 2018 | B2 |
11116669 | Gowans et al. | Sep 2021 | B2 |
20030212357 | Pace | Nov 2003 | A1 |
20040064132 | Boehringer et al. | Apr 2004 | A1 |
20040076662 | Riesinger | Apr 2004 | A1 |
20040087884 | Haddock et al. | May 2004 | A1 |
20040167482 | Watson | Aug 2004 | A1 |
20050012616 | Forster et al. | Jan 2005 | A1 |
20050045461 | Sweetland et al. | Mar 2005 | A1 |
20050065471 | Kuntz | Mar 2005 | A1 |
20050119737 | Bene et al. | Jun 2005 | A1 |
20050131327 | Lockwood et al. | Jun 2005 | A1 |
20050137539 | Biggie et al. | Jun 2005 | A1 |
20060029650 | Coffey | Feb 2006 | A1 |
20060086598 | Sneek et al. | Apr 2006 | A1 |
20060107642 | Smith et al. | May 2006 | A1 |
20060213527 | Argenta et al. | Sep 2006 | A1 |
20060259102 | Slatkine | Nov 2006 | A1 |
20070055209 | Patel et al. | Mar 2007 | A1 |
20070078366 | Haggstrom et al. | Apr 2007 | A1 |
20070128055 | Lee | Jun 2007 | A1 |
20070179460 | Adahan | Aug 2007 | A1 |
20070225663 | Watt et al. | Sep 2007 | A1 |
20070255187 | Branch | Nov 2007 | A1 |
20080021356 | Castello Escude | Jan 2008 | A1 |
20080051716 | Stutz | Feb 2008 | A1 |
20090012484 | Nielsen et al. | Jan 2009 | A1 |
20090048556 | Durand | Feb 2009 | A1 |
20100022990 | Karpowicz et al. | Jan 2010 | A1 |
20100100160 | Edman et al. | Apr 2010 | A1 |
20100137775 | Hu et al. | Jun 2010 | A1 |
20100160881 | Lin et al. | Jun 2010 | A1 |
20100280469 | Hall et al. | Nov 2010 | A1 |
20100292632 | Mulvihill et al. | Nov 2010 | A1 |
20110028918 | Hartwell | Feb 2011 | A1 |
20110112492 | Bharti et al. | May 2011 | A1 |
20110224631 | Simmons et al. | Sep 2011 | A1 |
20110292623 | Stanley | Dec 2011 | A1 |
20110305736 | Wieland et al. | Dec 2011 | A1 |
20120059294 | Schubert et al. | Mar 2012 | A1 |
20120109034 | Locke et al. | May 2012 | A1 |
20120253302 | Corley | Oct 2012 | A1 |
20130090615 | Jaeb et al. | Apr 2013 | A1 |
20130102979 | Coulthard et al. | Apr 2013 | A1 |
20130215638 | Dabov et al. | Aug 2013 | A1 |
20140100536 | Angel | Apr 2014 | A1 |
20140330227 | Coulthard et al. | Nov 2014 | A1 |
20140343518 | Riesinger | Nov 2014 | A1 |
20150057625 | Coulthard | Feb 2015 | A1 |
20150065965 | Haggstrom et al. | Mar 2015 | A1 |
20150174304 | Askem et al. | Jun 2015 | A1 |
20150202354 | Wall | Jul 2015 | A1 |
20150250931 | Bharti et al. | Sep 2015 | A1 |
20150258256 | Jaeb et al. | Sep 2015 | A1 |
20160015873 | Robinson et al. | Jan 2016 | A1 |
20160058927 | Weston | Mar 2016 | A1 |
20160081859 | Hartwell | Mar 2016 | A1 |
20160120706 | Collinson et al. | May 2016 | A1 |
20160166438 | Rovaniemi | Jun 2016 | A1 |
20160199546 | Chao | Jul 2016 | A1 |
20160206793 | Robinson et al. | Jul 2016 | A1 |
20160242964 | Rapp et al. | Aug 2016 | A1 |
20160271305 | Kurihara et al. | Sep 2016 | A1 |
20160361473 | Robinson et al. | Dec 2016 | A1 |
20170112974 | Fujisaki | Apr 2017 | A1 |
20170112975 | Fujisaki | Apr 2017 | A1 |
20170127525 | Schonholz | May 2017 | A1 |
20170232189 | Qin et al. | Aug 2017 | A1 |
20170296714 | Locke et al. | Oct 2017 | A1 |
20170304510 | Askem et al. | Oct 2017 | A1 |
20170319761 | Locke et al. | Nov 2017 | A1 |
20170326277 | Huang | Nov 2017 | A1 |
20180008760 | Zilbershlag et al. | Jan 2018 | A1 |
20180021178 | Locke et al. | Jan 2018 | A1 |
20180028728 | Aarestad et al. | Feb 2018 | A1 |
20180104393 | Wu et al. | Apr 2018 | A1 |
20180200414 | Askem et al. | Jul 2018 | A1 |
20180296397 | Askem et al. | Oct 2018 | A1 |
20180311078 | Hartwell | Nov 2018 | A1 |
20180318137 | Donda et al. | Nov 2018 | A1 |
20180318165 | Donda et al. | Nov 2018 | A1 |
20180353771 | Kim et al. | Dec 2018 | A1 |
20190021911 | Askem et al. | Jan 2019 | A1 |
20190110932 | Mumby et al. | Apr 2019 | A1 |
20190125943 | Askem et al. | May 2019 | A1 |
20190143007 | Askem et al. | May 2019 | A1 |
20190282737 | Beadle et al. | Sep 2019 | A1 |
20200022846 | Beadle et al. | Jan 2020 | A1 |
20210001022 | Lin | Jan 2021 | A1 |
Number | Date | Country |
---|---|---|
201664463 | Dec 2010 | CN |
19844355 | Apr 2000 | DE |
0512543 | Nov 1992 | EP |
1411874 | Apr 2004 | EP |
1455701 | Mar 2006 | EP |
1807032 | Jul 2007 | EP |
1476217 | Mar 2008 | EP |
1976477 | Oct 2008 | EP |
1507498 | Jul 2009 | EP |
1791579 | Jul 2009 | EP |
2109472 | Oct 2009 | EP |
1947987 | May 2010 | EP |
1358456 | Jul 2010 | EP |
2214728 | Aug 2010 | EP |
2279016 | Feb 2011 | EP |
2340064 | Jul 2011 | EP |
2346468 | Jul 2011 | EP |
2349155 | Aug 2011 | EP |
2205190 | Sep 2011 | EP |
2370116 | Oct 2011 | EP |
2531761 | Dec 2012 | EP |
2231088 | Jan 2013 | EP |
2015655 | Mar 2013 | EP |
2285323 | Mar 2013 | EP |
2563421 | Mar 2013 | EP |
2049055 | Apr 2013 | EP |
2340066 | Apr 2013 | EP |
2440260 | May 2013 | EP |
2340062 | Jun 2013 | EP |
2603699 | Jun 2013 | EP |
1893145 | Jul 2013 | EP |
2370142 | Jul 2013 | EP |
2279017 | Aug 2013 | EP |
2370117 | Aug 2013 | EP |
2258443 | Sep 2013 | EP |
2263742 | Sep 2013 | EP |
2659915 | Nov 2013 | EP |
1848390 | Dec 2013 | EP |
1875081 | Dec 2013 | EP |
2271381 | Dec 2013 | EP |
2160166 | Jan 2014 | EP |
1565219 | Feb 2014 | EP |
2305325 | Apr 2014 | EP |
2323712 | Apr 2014 | EP |
2345437 | Apr 2014 | EP |
2451498 | Apr 2014 | EP |
2051675 | Jun 2014 | EP |
1485613 | Jul 2014 | EP |
1545644 | Aug 2014 | EP |
2349154 | Aug 2014 | EP |
2146759 | Sep 2014 | EP |
2416816 | Oct 2014 | EP |
2468323 | Oct 2014 | EP |
2658493 | Oct 2014 | EP |
1850818 | Dec 2014 | EP |
2268348 | Dec 2014 | EP |
2561128 | Jan 2015 | EP |
2829287 | Jan 2015 | EP |
2683285 | Feb 2015 | EP |
2470136 | Mar 2015 | EP |
2503974 | May 2015 | EP |
2249894 | Aug 2015 | EP |
2802366 | Aug 2015 | EP |
2438302 | Sep 2015 | EP |
2346545 | Oct 2015 | EP |
2438301 | Oct 2015 | EP |
2802304 | Dec 2015 | EP |
2852421 | Jan 2016 | EP |
2410962 | Mar 2016 | EP |
2640436 | Mar 2016 | EP |
2855937 | May 2016 | EP |
2433594 | Jun 2016 | EP |
2919730 | Jun 2016 | EP |
2861869 | Jul 2016 | EP |
2945584 | Jul 2016 | EP |
2293749 | Aug 2016 | EP |
3072542 | Sep 2016 | EP |
2305327 | Oct 2016 | EP |
2467086 | Oct 2016 | EP |
2470135 | Oct 2016 | EP |
2767305 | Oct 2016 | EP |
2282788 | Dec 2016 | EP |
2462956 | Mar 2017 | EP |
3139878 | Mar 2017 | EP |
1587502 | May 2017 | EP |
1587554 | May 2017 | EP |
2731563 | May 2017 | EP |
2968871 | Jul 2017 | EP |
2632613 | Aug 2017 | EP |
2888478 | Aug 2017 | EP |
2937107 | Aug 2017 | EP |
2967627 | Aug 2017 | EP |
3062751 | Aug 2017 | EP |
3139879 | Aug 2017 | EP |
2359784 | Sep 2017 | EP |
3151795 | Sep 2017 | EP |
2367518 | Oct 2017 | EP |
2675493 | Oct 2017 | EP |
3068455 | Oct 2017 | EP |
2558046 | Nov 2017 | EP |
2736548 | Nov 2017 | EP |
3052158 | Nov 2017 | EP |
2593058 | Mar 2018 | EP |
3139880 | Mar 2018 | EP |
1496822 | Aug 2018 | EP |
2879633 | Aug 2018 | EP |
2227203 | Sep 2018 | EP |
2696826 | Sep 2018 | EP |
3106186 | Sep 2018 | EP |
3162330 | Sep 2018 | EP |
3169382 | Sep 2018 | EP |
3203953 | Sep 2018 | EP |
2941280 | Oct 2018 | EP |
3244852 | Oct 2018 | EP |
3062753 | Nov 2018 | EP |
3120879 | Dec 2018 | EP |
3191149 | Jan 2019 | EP |
2370130 | Mar 2019 | EP |
3053609 | Mar 2019 | EP |
3180048 | Mar 2019 | EP |
3143974 | Apr 2019 | EP |
2285432 | Jun 2019 | EP |
3050545 | Jul 2019 | EP |
3319656 | Aug 2019 | EP |
2355762 | Sep 2019 | EP |
2822613 | Sep 2019 | EP |
2863855 | Sep 2019 | EP |
2482912 | Oct 2019 | EP |
3038667 | Oct 2019 | EP |
3129095 | Oct 2019 | EP |
3191150 | Oct 2019 | EP |
3280466 | Oct 2019 | EP |
2244756 | Dec 2019 | EP |
2968702 | Dec 2019 | EP |
2939320 | Jun 2010 | FR |
2511523 | Sep 2014 | GB |
H04354722 | Dec 1992 | JP |
131622 | Aug 2013 | RU |
WO-2009098696 | Aug 2009 | WO |
WO-2009120951 | Oct 2009 | WO |
WO-2011049562 | Apr 2011 | WO |
WO-2011130570 | Oct 2011 | WO |
WO-2011135285 | Nov 2011 | WO |
WO-2011144888 | Nov 2011 | WO |
WO-2011146532 | Nov 2011 | WO |
WO-2013175306 | Nov 2013 | WO |
WO-2014099709 | Jun 2014 | WO |
WO-2016103031 | Jun 2016 | WO |
WO-2016126560 | Aug 2016 | WO |
WO-2016182977 | Nov 2016 | WO |
WO-2017079174 | May 2017 | WO |
WO-2017153357 | Sep 2017 | WO |
WO-2017186771 | Nov 2017 | WO |
WO-2017191154 | Nov 2017 | WO |
WO-2017196888 | Nov 2017 | WO |
WO-2018037075 | Mar 2018 | WO |
WO-2018056060 | Mar 2018 | WO |
WO-2018115461 | Jun 2018 | WO |
WO-2018156730 | Aug 2018 | WO |
WO-2018158250 | Sep 2018 | WO |
WO-2018162613 | Sep 2018 | WO |
WO-2018164803 | Sep 2018 | WO |
WO-2018185138 | Oct 2018 | WO |
WO-2018187394 | Oct 2018 | WO |
WO-2018192978 | Oct 2018 | WO |
WO-2018206420 | Nov 2018 | WO |
Entry |
---|
International Preliminary Report on Patentability for Application No. PCT/EP2017/071322, dated Mar. 7, 2019, 13 pages. |
International Search Report and Written Opinion for Application No. PCT/EP2016/059329, dated Jul. 14, 2016, 10 pages. |
International Search Report and Written Opinion for Application No. PCT/EP2017/071322, dated Nov. 30, 2017, 15 pages. |
Konark., “Electronics Overmolding: Silicone Overmolding: Konarksilicones,” Konark Silicone Technologies, available online at: http://www.konarksilicones.com/electronics-silicone-overmolding/, 2015, 2 pages. |
Owen, M .J. “Silicone Hydrophobicity and Oleophilicity,” Silicon 9, https://doi.org/10.1007/s12633-014-9188-0, 2017, pp. 651-655. |
Number | Date | Country | |
---|---|---|---|
20210401628 A1 | Dec 2021 | US |
Number | Date | Country | |
---|---|---|---|
62379667 | Aug 2016 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16328180 | US | |
Child | 17472436 | US |